Roofing and exterior contractors are not short on software. A growing contractor typically runs some mix of a CRM, a measurement tool, an accounting system, a supplier ordering portal, and a payment processor. What’s missing is the layer that can help tie those tools together.

<p>VANCOUVER, Wash.--(BUSINESS WIRE)--September 29, 2026--</p><p> ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, has launched a <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsuperhuman.com%2Fstore%2Fconnectors%2Fzoominfo-55877%3Fref%3Dblog.superhuman.com&amp;esheet=54612581&amp;newsitemid=20260929354821&amp;lan=en-US&amp;anchor=connector&amp;index=1&amp;md5=755509755117afaad8f684750fda8e56" shape="rect">connector</a> for <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsuperhuman.com%2Fgo&amp;esheet=54612581&amp;newsitemid=20260929354821&amp;lan=en-US&amp;anchor=Superhuman+Go&amp;index=2&amp;md5=11caf211ac7c27ea0d5b05939d7d65ae" shape="rect">Superhuman Go</a>, the AI assistant from Superhuman that works wherever people work. The integration allows mutual customers to bring ZoomInfo's verified GTM intelligence data into Superhuman Go, so the context users need comes to them in the apps they’re already working in. </p><p> The connector reads directly from GTM.AI, ZoomInfo's headless GTM context layer, through the same API and Model Context Protocol (MCP) interface that already powers integrations across ZoomInfo's GTM Context Graph, which spans 100 million companies, 500 million contacts, and billions of buying signals. With the connector, users can search for target accounts by industry size or tech stack and pull verified contacts by title and seniority directly into where they’re working. They can also surface intent signals and generate a full account or contact brief before sales meetings. </p><p> “Superhuman Go is built to bring the right intelligence and assistance to people wherever work happens,” said Jessica Gates, Director of ISV Partnerships. “With ZoomInfo’s GTM Context Graph available through a native connector, our customers can bring verified company, contact, and buying-signal context into the workflows they already use. This gives revenue teams more relevant context at the moment they need it, helping them prepare faster, personalize engagement, and focus on moving opportunities forward.” </p><p> Superhuman Go joins a growing list of GTM.AI integrations, including Salesforce Agentforce, HubSpot Breeze, Microsoft Copilot Studio, Gong, LeanData, Claude, ChatGPT, and Google Workspace, all reading from the same verified data graph. </p><p> Authentication and governance stay tied to each customer's existing ZoomInfo and Superhuman permissions. Access control, data lineage, and audit logging apply to the Superhuman Go connection the same way they apply across every other GTM.AI integration. </p><p> The ZoomInfo connector is available to add now for Superhuman Go customers with a ZoomInfo subscription. Connect today at: <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsuperhuman.com%2Fstore%2Fconnectors%2Fzoominfo-55877&amp;esheet=54612581&amp;newsitemid=20260929354821&amp;lan=en-US&amp;anchor=https%3A%2F%2Fsuperhuman.com%2Fstore%2Fconnectors%2Fzoominfo-55877&amp;index=3&amp;md5=55bf2cedc0b2e91dce6752178ac34c88" shape="rect">https://superhuman.com/store/connectors/zoominfo-55877</a> </p><p> About ZoomInfo </p><p> ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, enables sales, marketing, and customer success teams to execute their go-to-market strategy with confidence. Powered by the industry's most comprehensive B2B data, including more than 100 million companies, 500 million contacts, and billions of signals, ZoomInfo delivers the intelligence, automation, and integrations that modern revenue teams need to identify, engage, and convert their best buyers. </p><p> GTM.AI is ZoomInfo's headless GTM context layer. It is the API and Model Context Protocol home for AI agents, powering integrations across Salesforce Agentforce, HubSpot Breeze, Microsoft Copilot, Claude, ChatGPT, and dozens more. </p><p> Learn more at <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zoominfo.com%2F&amp;esheet=54612581&amp;newsitemid=20260929354821&amp;lan=en-US&amp;anchor=zoominfo.com&amp;index=4&amp;md5=242b9c7f38aa9ca1f252d8a170728832" shape="rect">zoominfo.com</a> and <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fgtm.ai&amp;esheet=54612581&amp;newsitemid=20260929354821&amp;lan=en-US&amp;anchor=gtm.ai&amp;index=5&amp;md5=21f2cfa394d47231dc8190775706dc05" shape="rect">gtm.ai</a>. </p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260929354821r1&amp;sid=ventb&amp;distro=nx&amp;lang=en" style="width:0;height:0"><span class="bwct31415"></span></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link"><a href="https://www.businesswire.com/news/home/20260929354821/en/" rel="nofollow">https://www.businesswire.com/news/home/20260929354821/en/</a></span></p><p> <b>Media contact: </b>Public Relations Team, ZoomInfo: <a rel="nofollow" href="mailto:PR@zoominfo.com" shape="rect">PR@zoominfo.com</a> </p>

<p><strong></strong></p><p class="bwalignc"><strong> <i>Approval supported by a multicenter, randomized, subject- and evaluator-blinded pivotal study</i> </strong></p><p></p><p>BEDFORD, Mass.--(BUSINESS WIRE)--September 29, 2026--</p><p> Rejoni, Inc., a commercial-stage women's health company focused on uterine health, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA<b> </b>P250051) for the Juveena Hydrogel System. The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. </p><p> Intrauterine adhesions (IUAs) can form inside the uterus following trauma to the endometrium and may lead to menstrual disruption, infertility, recurrent pregnancy loss, and serious obstetric complications. Recurrence after surgical removal of IUAs is common, and women with severe disease often face repeated procedures. Juveena is designed to protect the uterine cavity during the healing period after adhesiolysis to reduce the incidence and severity of IUAs. </p><p> The Juveena hydrogel is delivered through a proprietary transcervical catheter at the end of the hysteroscopic procedure. Once placed, the hydrogel forms in situ, conforms to the uterine cavity, and separates uterine walls. Within approximately 14 to 21 days, the hydrogel softens, liquefies, and is naturally discharged through the cervix and vagina. </p><p> <b>Pivotal Trial Results</b> </p><p> FDA approval is supported by the Juveena Pivotal Study, a multicenter, randomized, subject- and evaluator-blinded controlled study conducted at 15 U.S. centers. Women were randomized 2:1 to Juveena or surgery alone, with randomization stratified by procedure type, and underwent second-look hysteroscopy approximately eight weeks after surgery. The primary endpoint, adhesion-free rate, was adjudicated by a blinded Central Review Committee using paired video review. The study met its primary endpoint, the percentage of patients free of adhesions at week 8, in the overall study population. Results for women treated after hysteroscopic adhesiolysis for symptomatic moderate to severe IUAs, the population for which Juveena is approved, as reported in the FDA-approved labeling: </p><ul class="bwlistdisc"> <li> <b>Adhesion-free rate after adhesiolysis (descriptive subgroup analysis):</b> 61.5% of Juveena-treated women were free of intrauterine adhesions at week 8, compared with 38.2% of controls. </li> <li> <b>Lower adhesion severity (prespecified secondary endpoint):</b> Adhesion severity at week 8 was significantly lower with the Juveena Hydrogel System than with control (p=0.001). Severe adhesions were seen in 6.1% of Juveena patients vs. 28.6% of controls. </li> <li> <b>Safety:</b> In the overall safety population, adverse events attributed to the device occurred in 8% of Juveena patients: uterine spasm, pelvic discomfort, pelvic pain, dysmenorrhea, and one device expulsion. All were non-serious; most were mild or moderate, and all resolved with no intervention or conservative medical management. </li> </ul><p> “Recurrence of IUAs after adhesiolysis has been a persistent problem with few good options,” said John Nealon, President and Chief Executive Officer of Rejoni, Inc. “This approval gives surgeons a tool backed by rigorous scientific evidence. We are excited to bring this innovation to physicians and their patients very soon.” </p><p> "For women with moderate to severe intrauterine adhesions, protecting the uterine cavity after surgery is critical," said Pietro Bortoletto, M.D., reproductive endocrinologist and co-founder of Terra Fertility in Dedham, Mass. "As an investigator in the Juveena pivotal study, I saw its impact on my patients firsthand, and I'm excited to now offer it as part of my standard of care." </p><p> <b>Launch and Availability</b> </p><p> Rejoni will initiate a limited market release of Juveena at select U.S. centers specializing in hysteroscopic surgery and reproductive medicine, followed by a broader commercial rollout. The company has established a patient access program to support coverage and reimbursement. Juveena procedures may be reported using CPT Category III code 0990T. </p><p> <b>About the Juveena Hydrogel System</b> </p><p> The Juveena Hydrogel System is an in situ-forming hydrogel designed to help reduce the incidence and severity of intrauterine adhesions following hysteroscopic adhesiolysis. Delivered transcervically as a liquid, it forms a temporary hydrogel spacer that conforms to the uterine cavity and keeps the uterine walls apart while they heal. </p><p> <b>Important Safety Information</b> </p><p> The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. The Juveena Hydrogel System should not be used in patients with hemorrhage, active pelvic infection, sexually transmitted disease, or pregnancy, or in patients with known hypersensitivity or allergy to polyethylene glycol (PEG) or FD&amp;C Blue #1 dye. Safety and effectiveness have not been established following hysteroscopic procedures other than adhesiolysis of moderate to severe intrauterine adhesions, or in patients undergoing thermal endometrial ablation. Patients should avoid pregnancy during the first complete menstrual cycle after treatment. Potential adverse reactions include discomfort, pain/cramping, infection, local inflammatory reaction, and allergic reaction. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician or licensed practitioner. For complete information, see the Instructions for Use. </p><p> <b>About Rejoni, Inc.</b> </p><p> Rejoni, Inc. is a privately held, commercial-stage company based in Bedford, Massachusetts, that is developing and commercializing gynecological products based on its proprietary biomaterials, including the Juveena® Hydrogel System. Founded in 2020, Rejoni is the latest company started by serial entrepreneur Amar Sawhney, who also founded Confluent Surgical, Ocular Therapeutix, and Augmenix. More information is available at <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rejoni.com&amp;esheet=54612393&amp;newsitemid=20260929309102&amp;lan=en-US&amp;anchor=www.rejoni.com&amp;index=1&amp;md5=4dc0a4a635f9face8a3869a766e5da23" shape="rect">www.rejoni.com</a>. </p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260929309102r1&amp;sid=ventb&amp;distro=nx&amp;lang=en" style="width:0;height:0"><span class="bwct31415"></span></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link"><a href="https://www.businesswire.com/news/home/20260929309102/en/" rel="nofollow">https://www.businesswire.com/news/home/20260929309102/en/</a></span></p><p> <b>Media Contact </b><br>Nicole Shugrue, VP Market Development, Rejoni, Inc. <br><a rel="nofollow" href="mailto:nicole.shugrue@rejoni.com" shape="rect">nicole.shugrue@rejoni.com </a><br>781-222-0081 <br>REJ-MKT-0042 Rev. A </p>